Response rates
Variables . | Bortezomib . | Control . | Test* . | ||
---|---|---|---|---|---|
n . | % (n) . | n . | % (n) . | P value . | |
At randomization | 179† | 180† | |||
≥nCR | 20.1 (36) | 20.6 (37) | |||
VGPR | 19.6 (35) | 18.3 (33) | |||
PR | 51.4 (92) | 50.0 (90) | |||
MR | 7.3 (13) | 8.9 (16) | |||
SD | 1.7 (3) | 2.2 (4) | |||
Best response | 182‡ | 183 | |||
≥nCR | 45.1 (82) | 35.0 (64) | |||
VGPR | 25.8 (47) | 22.4 (41) | |||
PR | 25.3 (46) | 38.3 (70) | |||
MR | 2.7 (5) | 3.3 (6) | |||
SD | 0.5 (1) | 0.5 (1) | |||
PD | 0.5 (1) | 0.5 (1) | |||
≥nCR | 45.1 (82) | 35.0 (64) | .055 | ||
≥VGPR | 70.9 (129) | 57.4 (105) | .0088 |
Variables . | Bortezomib . | Control . | Test* . | ||
---|---|---|---|---|---|
n . | % (n) . | n . | % (n) . | P value . | |
At randomization | 179† | 180† | |||
≥nCR | 20.1 (36) | 20.6 (37) | |||
VGPR | 19.6 (35) | 18.3 (33) | |||
PR | 51.4 (92) | 50.0 (90) | |||
MR | 7.3 (13) | 8.9 (16) | |||
SD | 1.7 (3) | 2.2 (4) | |||
Best response | 182‡ | 183 | |||
≥nCR | 45.1 (82) | 35.0 (64) | |||
VGPR | 25.8 (47) | 22.4 (41) | |||
PR | 25.3 (46) | 38.3 (70) | |||
MR | 2.7 (5) | 3.3 (6) | |||
SD | 0.5 (1) | 0.5 (1) | |||
PD | 0.5 (1) | 0.5 (1) | |||
≥nCR | 45.1 (82) | 35.0 (64) | .055 | ||
≥VGPR | 70.9 (129) | 57.4 (105) | .0088 |